Marina Chiara Garassino to Response Evaluation Criteria in Solid Tumors
This is a "connection" page, showing publications Marina Chiara Garassino has written about Response Evaluation Criteria in Solid Tumors.
Connection Strength
0.243
-
Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study. Lancet Oncol. 2018 04; 19(4):521-536.
Score: 0.159
-
Efficacy and safety of immunotherapy in elderly patients with non-small cell lung cancer. Lung Cancer. 2019 11; 137:38-42.
Score: 0.044
-
The evolving landscape of criteria for evaluating tumor response in the era of cancer immunotherapy: From Karnofsky to iRECIST. Tumori. 2018 Mar-Apr; 104(2):88-95.
Score: 0.040